Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study
Ashley S. Felix(Wake Forest University), Louise A. Brinton(National Cancer Institute), Michael L. Pearl(Stony Brook University), Marcus E. Randall(University of Kentucky), Kay J. Park(Memorial Sloan Kettering Cancer Center), Premal H. Thaker(Washington University in St. Louis), John F. Boggess(University of Kentucky), Richard G. Moore(University of Rochester Medical Center), Joan L. Walker(Cornell University), Saketh R. Guntupalli(University of Colorado Cancer Center), Shashikant Lele(Memorial Sloan Kettering Cancer Center), Richard J. Zaino(Pennsylvania State University), David G. Mutch(Cancer Research Center), David E. Cohn(The Ohio State University), Christa Nagel(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Levi S. Downs(University of Toronto), Theodore M. Brasky(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), William T. Creasman(Medical University of South Carolina), Olga B. Ioffe(University of Maryland, Baltimore)
Cited by 16
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k